PET Scans May Soon Show Which Gut Bacteria Are Active — And Where

A team of researchers is working to turn PET scanners — the powerful imaging machines typically used to track cancer or heart disease — into windows onto the living gut microbiome. A new study describes a multi-tracer imaging strategy designed to identify which bacterial communities are metabolically active and to pinpoint exactly where in the gastrointestinal tract they are operating at any given moment.

The approach uses three radioactive tracer compounds: fluorodeoxyglucose, fluorodeoxysorbitol, and choline. Each tracer is taken up differently depending on which bacteria are present and active in a given region of the gut. Think of it as leaving three distinct types of bait in different rooms of a house — the bait that disappears fastest reveals which inhabitants are hiding where, and in what numbers.

The scientific rationale runs deep into disease biology. The way gut bacteria interact with dietary sugars like glucose and sorbitol, and with choline — a nutrient found abundantly in eggs, meat, and legumes — has been independently linked to the development of multiple chronic conditions. Disruptions in choline metabolism by gut bacteria have been associated with cardiovascular disease and metabolic disorders. Sugar fermentation patterns, meanwhile, shape the inflammatory environment of the gut and exert wide-ranging effects on systemic health in ways researchers are still actively mapping.

The two bacterial classes identified by the imaging — Clostridia and Lactobacillales — are not obscure microbes. Clostridia species are well-studied fermenters whose imbalance has been implicated in conditions ranging from inflammatory bowel disease to metabolic syndrome. Lactobacillales, the class that includes familiar probiotic strains, are central players in gut barrier integrity and immune regulation. Being able to observe both classes in their natural gastrointestinal location, rather than inferring their presence from stool data, is a meaningful methodological leap.

Current methods for studying the gut microbiome rely heavily on stool samples, which reveal what bacteria are present but offer limited insight into location or real-time metabolic activity. A validated PET-based approach could change that equation significantly, providing functional information about bacterial behavior throughout the gastrointestinal tract without invasive procedures. For a field where linking specific microbial activity to disease outcomes has long been a methodological bottleneck, this multi-tracer imaging strategy represents a potentially meaningful new tool — one that could eventually connect what bacteria are doing inside the body to how chronic diseases begin and progress.